Novo Nordisk A/S (NVO) Receives Consensus Rating of “Hold” from Analysts

Shares of Novo Nordisk A/S (NYSE:NVO) have earned a consensus recommendation of “Hold” from the seventeen analysts that are currently covering the firm, MarketBeat reports. Five investment analysts have rated the stock with a sell rating, seven have issued a hold rating and four have issued a buy rating on the company.

A number of brokerages have recently issued reports on NVO. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Monday, July 17th. TheStreet upgraded shares of Novo Nordisk A/S from a “c+” rating to a “b-” rating in a research report on Tuesday, May 2nd. Finally, BidaskClub upgraded shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Thursday, June 15th.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Guggenheim Capital LLC increased its position in Novo Nordisk A/S by 4.3% in the fourth quarter. Guggenheim Capital LLC now owns 35,235 shares of the company’s stock worth $1,264,000 after buying an additional 1,442 shares during the last quarter. Norman Fields Gottscho Capital Management LLC increased its position in Novo Nordisk A/S by 9.2% in the first quarter. Norman Fields Gottscho Capital Management LLC now owns 37,930 shares of the company’s stock worth $1,300,000 after buying an additional 3,200 shares during the last quarter. Raymond James Trust N.A. increased its position in Novo Nordisk A/S by 10.4% in the first quarter. Raymond James Trust N.A. now owns 19,837 shares of the company’s stock worth $680,000 after buying an additional 1,866 shares during the last quarter. Creative Planning increased its position in Novo Nordisk A/S by 63.3% in the first quarter. Creative Planning now owns 40,622 shares of the company’s stock worth $1,393,000 after buying an additional 15,746 shares during the last quarter. Finally, Douglass Winthrop Advisors LLC increased its position in Novo Nordisk A/S by 2.8% in the first quarter. Douglass Winthrop Advisors LLC now owns 18,300 shares of the company’s stock worth $627,000 after buying an additional 500 shares during the last quarter. Institutional investors own 6.40% of the company’s stock.

Shares of Novo Nordisk A/S (NYSE NVO) traded up 4.01% during trading on Tuesday, reaching $45.92. 1,632,713 shares of the company traded hands. The company has a 50 day moving average price of $42.69 and a 200 day moving average price of $38.73. The firm has a market capitalization of $113.95 billion, a price-to-earnings ratio of 18.78 and a beta of 0.63. Novo Nordisk A/S has a 12-month low of $30.89 and a 12-month high of $47.98.

The business also recently announced an annual dividend, which will be paid on Tuesday, August 29th. Investors of record on Monday, August 21st will be given a dividend of $0.336 per share. This represents a dividend yield of 1.07%. The ex-dividend date is Friday, August 18th. This is an increase from Novo Nordisk A/S’s previous annual dividend of $0.33. Novo Nordisk A/S’s payout ratio is presently 35.84%.

COPYRIGHT VIOLATION WARNING: “Novo Nordisk A/S (NVO) Receives Consensus Rating of “Hold” from Analysts” was first published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at https://www.baseball-news-blog.com/2017/08/19/novo-nordisk-as-nvo-receives-consensus-rating-of-hold-from-analysts-updated-updated.html.

About Novo Nordisk A/S

Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company’s diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs.

Analyst Recommendations for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply